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Abstract
Objectives: Positron emission tomography–magnetic resonance imaging (PET/MRI)
is an emerging hybrid imaging system in clinical nuclear medicine. Research dem-
onstrates a comparative utility to current unimodal and hybrid methods, including
PET‐computed tomography (PET/CT), in several medical subspecialities such as
neuroimaging. The aim of this review is to critically evaluate the literature from
2016 to 2021 using PET/MRI for the investigation of patients with mild cognitive
impairment or dementia, and discuss the evidence base for widening its application
into clinical practice.
Methods: A comprehensive literature search using the PubMed database was
conducted to retrieve studies using PET/MRI in relation to the topics of mild
cognitive impairment, dementia, or Alzheimer's disease between January 2016 and
January 2021. This search strategy enabled studies on all dementia types to be
included in the analysis. Studies were required to have a minimum of 10 human
subjects and incorporate simultaneous PET/MRI.
Results: A total of 116 papers were retrieved, with 39 papers included in the final
selection. These were broadly categorised into reviews (12), technical/methodo-
logical papers (11) and new data studies (16). For the current review, discussion
focused on findings from the new data studies.
Conclusions: PET/MRI offers additional insight into the underlying anatomical,
metabolic and functional changes associated with dementia when compared with
unimodal methods and PET/CT, particularly relating to brain regions including the
hippocampus and default mode network. Furthermore, the improved diagnostic
utility of PET/MRI, as reported by radiologists, offers improved classification of
dementia patients, with important implications for clinical management.
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Key Points
� Combined positron emission tomography–magnetic resonance imaging (PET/MRI) is an
emerging imaging technique in clinical nuclear medicine.
� PET/MRI is predominantly used as a research tool in dementia.
� Improved diagnostic accuracy of PET/MRI compared to unimodal methods and PET/CT is
demonstrated in other subspecialities.
� Awareness of the clinical utility of PET/MRI in dementia is growing, with earlier diagnosis
having important implications for patient management.
1 | INTRODUCTION
1.1 | Background
Nuclear medicine today includes hybrid imaging modalities such as
combined positron emission tomography (PET) and computed to-
mography (CT), improving on previously used PET‐only cameras. The
increased diagnostic accuracy of PET/CT, in addition to the reduction
in emission scan time resulting from both lutetium‐based PET scin-
tillators, and CT‐based attenuation correction1 resulted in an
economically viable product for widespread clinical use. Prior to the
commercialisation of PET/CT, the concept of combining PET with
magnetic resonance imaging (MRI) was already being tested,2–4 with
the first human application of PET/MRI only appearing relatively
recently in the literature, initially assessing feasibility.5,6
Multiple considerations are needed when combining the two
methods, such as the effect on electron flow in PET as a result of both
static and gradient magnetic fields, as well as the disruption to the
uniformity of the magnetic field resulting from PET components
being placed in the MRI scanner bore.7,8 Methods developed to
overcome such technical issues are highlighted by the presence of
three whole‐body PET/MRI systems utilising different approaches
created by GE Health Care, Philips Healthcare, and Siemens.9
Despite the significant economic and technical barriers, the
motivation to advance the use of PET/MRI within routine clinical
practice stems from the superior structural information provided by
MRI compared to CT, as well as the technical advantages of improved
coregistration, and service benefits associated with reducing scan-
ning time. Using radiotracers, PET relies on the production of gamma
rays from positron decay to provide functional information based on
blood flow, glucose or oxygen consumption, protein synthesis, or
neuroreceptor uptake.10 Whilst PET has high specificity, anatomical
information varies according to tracer used. MRI utilises a magnetic
field and radiofrequency pulse to influence the axial spin of hydrogen
protons, abundant in water and fat, with the energy emitted during
proton relaxation used to produce highly sensitive structural im-
ages.11 Compared to PET/CT, the soft tissue contrast, multiplanar
capability, and reduced radiation dose offered by PET/MRI makes it
an increasingly attractive tool, particularly within neuroimaging.
1.2 | PET/MRI in neuroimaging
Whilst used clinically in cardiology,12 orthopaedics13 and
oncology,14–17 the first human research PET/MRI images were of the
brain.6 PET imaging in the examination of neurotransmitter activity,
neuroinflammation and haemodynamic compromise in ischaemic
stroke is well‐established.18–22 Conversely, MRI is the gold standard
in the assessment of brain tumours,23 as well as in the detection of
white matter (WM) damage in multiple sclerosis.24–26 Combined,
the advantages of PET/MRI in neurological investigation are
increasingly documented, including the increased sensitivity of
18F‐fluorodeoxyglucose (FDG) PET/MRI in differentiating post-
therapy tumour recurrence from fibrosis, in addition to an improved
accuracy in targeting radiotherapy volumes, and overall superior
image quality and artefact reduction.27–29 Additionally, studies
investigating epileptic seizure focus have shown PET/MRI to be a
valid alternative to PET/CT in paediatric populations, particularly due
to the reduced radiation exposure.30
1.3 | PET/MRI in people with dementia
Patients undergoing cognitive assessment often require routine MRI
and PET imaging. MRI techniques such as diffusion tensor imaging
(DTI) and functional MRI (fMRI) assist in examining functional con-
nectivity networks implicated in dementia, such as the default mode
network (DMN) composed of regions including the medial prefrontal
cortex, angular gyrus and posterior cingulate cortex.31,32 Conversely,
PET has been used in differentiating clinical subtypes of dementia
based on patterns of brain metabolism.33 Recent amyloid PET ra-
diotracers such as [11C]‐Pittsburgh compound‐B (PIB) and fluori-
nated tracers which have now become licensed for clinical use
provide additional information on β‐amyloid plaque pathology asso-
ciated with dementias such as Alzheimer's disease (AD), improving
understanding of disease prevention and progression.34 Integration
of these methods to assist diagnosis and treatment of dementia is
subsequently of great interest to clinicians, with the added benefit of
single session multimodal image acquisition being an important
consideration for patients who are often elderly or frail.35
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1.4 | The current review
Currently, PET/MRI use in dementia is predominantly research‐based,
with the Dementias Platform UK establishing an innovative dementia
imaging network linking PET/MRI scanners at seven UK universities,
with an aim to support large scale research and clinical trials.36 The
purposeof this review is to critically examine themost recent literature
published between 2016 and 2021 on the use of PET/MRI in dementia,
evaluating how it compares to unimodal approaches, and discuss
the evidence base for widening its application into clinical practice.
2 | METHODS
2.1 | Literature search
A literature search on the use of PET‐MRI in dementia was per-
formed in the PubMed database. The MeSH terms used to search the
database were (“PET‐MR” OR “PET‐MRI”) AND (“Dementia” OR
“Mild cognitive impairment” OR “Alzheimer”). The search was un-
dertaken on 15th January 2021 and included all papers published
from 1st January 2016 until then. The search was designed to ensure
that relevant papers on all dementias would be captured, as well as
papers which used the term AD (rather than Alzheimer's dementia)
and studies of those with mild cognitive impairment.
2.2 | Study selection
The inclusion criteria used to screen for eligibility required papers to
have been published in the last 5 years, in English, with a minimum of
10 human subjects. Additionally, only papers employing simultaneous
PET/MRI imaging relating to the topic of dementia or mild cognitive
impairment were selected. Papers comparing the utility of different
PET radiotracers, using PET or MRI imaging separately, reports of
animal studies, or papers relating to other neurological or neurode-
generative diseases were excluded from selection. Using these
criteria, two researchers separately reviewed the titles and abstracts
for relevance to agree a final list for inclusion.
3 | RESULTS
The results of the literature search are illustrated in Figure 1. Of the
116 studies identified using the search, 39 papers were included in
the final selection, and they can be broadly categorised into 1) review
F I GUR E 1 Flow chart demonstrating
selection process of retrieved articles from
literature search
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articles, 2) technical or methodological papers and 3) new data pa-
pers on patients with MCI or dementia. Full text analysis was not
possible for one paper due to restricted access, with the findings
presented in the abstract being used to inform the current review. A
summary of the aims and main findings of the new data papers is
shown in Table 1.
4 | DISCUSSION
A third of papers retrieved were review articles, highlighting an
increased awareness of PET/MRI and its potential applications for
dementia. Technical papers focused predominantly on attenuation
correction, with results largely demonstrating the comparative effi-
cacy of MRI‐based techniques with CT‐AC. Whilst these papers
address important challenges faced when commercialising PET/MRI,
for the purposes of this review, discussion will focus on the new data
studies retrieved to assess the utility of PET/MRI as a clinical tool in
dementia.
4.1 | Hippocampal studies
MRI evidence of medial temporal lobe atrophy, involving structures
such as the hippocampus, entorhinal, and perirhinal cortices is well‐
documented in dementia.53,54 Hippocampal regions including the
cornu ammonis, and dentate gyrus are often smaller in AD/MCI pa-
tients,55 an important biomarker for predicting AD onset.56,57 These
areas also demonstrate reduced 18F‐FDG‐uptake in PET studies.58
Limited studies have investigated hippocampal structural and meta-
bolic changes using PET/MRI. Carlson et al.40 employed 18F‐FDG‐
PET/MRI and automated hippocampal subfield‐segmentation in AD/
MCI patients, finding significantly lower dentate gyrus and cornu
ammonis volumes, and reduced dentate gyrus FDG‐SUVr compared
to controls. Whole hippocampal SUVr values were not significantly
different between groups. These findings support previous studies
using unimodal PET and MRI, implicating the early involvement of
cornu ammonis and dentate gyrus in neurodegenerative processes.
However, Carlson et al. further demonstrated that at a single time‐
point, in the same individuals, hippocampal atrophy is more pro-
nounced than hypometabolism, as structural differences between
hippocampal regions, and between groups, were significantly more
varied than SUVr values. Such findings are difficult to extrapolate
from unimodal imaging studies, and may provide further insight into
useful biomarkers of early disease onset. However, hippocampal
volumes are shown to be influenced by early life factors, potentially
affecting individual baseline values.59 Additionally, AD/MCI patients
were grouped together to increase statistical power, which may in-
fluence the applicability of these findings to patients at varying dis-
ease stages. Despite this, the authors noted an improved spatial
alignment between PET and MRI images due to intrinsic scanner
coregistration, reducing issues such as misalignment and spatial in-
tensity distortion associated with coregistering unimodal images.60
Kang et al.39 similarly used automated brain segmentation soft-
ware and [11C]PiB PET/MRI to demonstrate the predictive ability of
hippocampal regional volume on the presence of Aβ, an important
predictor of dementia development.61 These findings support the
association between early memory deficits and hippocampal atro-
phy,55 and further demonstrate the relationship between these
structural changes and developing Aβ pathology in MCI. Although
MRI is widely used to assess structural abnormalities associated with
neurodegeneration,55 the additional screening for Aβ load using [11C]
PiB has important clinical implications for PET/MRI, as earlier
detection of such biomarkers improves opportunities for active
intervention. However, this study also assessed the utility of a newly
approved segmentation software, with more studies applying this
specific package to PET/MRI needed to substantiate their findings.
Additionally, risk factors such as cardiovascular disease, which have
the potential to confound brain volume assessment, were not
accounted for in patient selection or statistical analyses. Despite
these limitations, Kang et al. demonstrate the utility of PET/MRI in
predicting early Aβ pathology using multimodal parameters in a
single imaging session.
A further study by Yan et al.51 used PET/fMRI to investigate the
relationship between hippocampal structure and metabolism, and
resulting effects on functional connectivity in AD/MCI patients. Re-
sults showed a significant reduction in both 18F‐FDG‐SUVr and
functional connectivity in most hippocampal subregions in AD pa-
tients, and significantly reduced connectivity between the hippo-
campus and frontal regions including the superior medial frontal
gyrus and precuneus, supporting previous fMRI and PET studies.62
Researchers also reported a significant negative correlation between
18F‐FDG hypometabolism and decreased left cornu ammonis/dentate
gyrus‐superior medial frontal gyrus connectivity in AD patients, a
finding corresponding to previous fMRI studies showing that
increased activity in cornu ammonis/dentate gyrus is associated with
reduced cognitive function,63 and can be therapeutically targeted.64
The relationship between hippocampal functional connectivity and
metabolism demonstrated by PET/fMRI in this study improves on
previous findings using unimodal techniques, and allows for a more
comprehensive understanding of underlying neurodegenerative
processes occurring at the subregional hippocampal level.
4.2 | Functional connectivity studies
The default mode network is a tightly connected functional brain
network important in memory function, studied previously using
predominantly fMRI.31,32 Employing 18F‐FDG‐PET/fMRI, Marchitelli
et al.46 investigated the relationship between glucose metabolism
and neuronal activity in patients with AD/MCI, and examined within‐
subject correlations between 18FDG‐PET and fMRI metrics
measuring local connectivity and spatiotemporal patterns. Both
18FDG‐PET and fMRI metrics independently differentiated AD/MCI
patients from healthy controls, with posterior DMN regions exhib-
iting the greatest changes. Similar findings using PET/MRI are
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reported by both Ding et al.50 and Scherr et al.52 Moreover, within‐
subject PET/fMRI correlations showed a 17% reduction in AD/MCI
patients compared to controls. These findings support prior unimodal
studies65–67 and go further to provide evidence for the theory that
glucose‐mediated CBF regulation and glucose/oxygen coupling de-
teriorates with AD disease progression.68
Limitations of this study include the finding that DMN hypo-
metabolism in AD/MCI patients was more extensive than patterns of
hypoconnectivity. 18FDG metabolism reflects resting‐state glucose
mobilisation and is largely unaffected by physiological artefacts,69
whereas the blood‐oxygen level‐dependent (BOLD) signal is a hae-
modynamic measure of oxygen consumption, and can be influenced
by altered physiological conditions.70 These differences could
therefore bias the combined used of PET/fMRI metrics when inter-
preting underlying DMN changes in AD/MCI. However, Göttler
et al.47 found that whilst overlapping changes in BOLD signal, 18FDG
uptake, and CBF were found in the DMN of AD patients, reductions
in BOLD signal were correlated with reduced CBF independently
from 18FDG‐PET hypometabolism. This suggests that altered BOLD
signals found in AD/MCI patients can reflect impairments in hae-
modynamic processes separately from changes in neuronal activity.
Regional reductions in CBF for AD patients was also found by Oka-
zawa41 and Riederer.45 Altogether, the use of both fMRI BOLD signal
and 18FDG‐PET data in these studies allows for a unique insight into
simultaneous neurodegenerative processes underlying AD in a way
that cannot be achieved using unimodal imaging methods.
PET/MRI has also been used to investigate WM tracts forming
the basis of functional brain networks such as the DMN, as WM
damage is consistently observed in AD postmortem studies.71 There
is also increasing evidence that neurodegeneration spreads via brain
networks.72 DTI, an MRI method based on the measurement of water
molecule diffusion in different tissues, has demonstrated WM
changes in AD patients.73 Dong et al.42 used amyloid tracer 18F‐
Florbetapir and PET/DTI‐MRI to examine the relationship between
WM changes and Aβ deposition in AD/MCI patients, demonstrating
WM changes in tracts such as the anterior corona radiata and genu of
the corpus callosum. The benefits of integrating MRI techniques with
PET amyloid tracers is further highlighted by Tiepolt38 who combined
[11C]PiB‐PET with quantitative susceptibility mapping, an MRI tech-
nique measuring the magnetic susceptibility of brain regions as a
consequence of iron deposition. Findings suggested a relationship
between Aβ load and putaminal iron deposition in AD patients.
Although this requires further investigation, additional discoveries of
such biomarkers is possible if PET/MRI were more widely available.
Moving beyond the cerebrum, Franceschi et al.37 used 18FDG‐
PET/MRI to examine neurodegeneration within the corticopontine‐
cerebellar pathway. Results showed decreased 18FDG activity in
the contralateral cerebellar hemisphere to supratentorial hypo-
metabolism, providing support for the presence of crossed cerebellar
diaschisis in dementia, a common finding in neurological disease, and
further demonstrated this to be more common in FTD compared to
other dementias. Although further research is needed to clarify the
relationship between PET and MRI metrics when examining
functional connectivity in dementia, the overall benefit shown by
these studies of simultaneous image acquisition at a single point in
time and physiological state is important for advancing understand-
ing of disease stage and pathology, with subsequent implications for
earlier clinical intervention.
4.3 | Diagnostic utility
An important consideration for the clinical applicability of PET/MRI
in dementia is the perception of clinical utility. Compared to other
cerebral disorders (e.g., tumours, stroke), dementia and associated
pathology is underemphasised in radiology teaching, with few
radiological reports suggesting dementia diagnoses despite identifi-
cation of characteristic atrophy patterns.74 In practice, MRI and PET
images are often interpreted by different subspecialist radiologists,
with integration of these separate findings often left to the referring
clinician.75 Mukku et al.43 examined the diagnostic utility of 18FDG‐
PET/MRI in dementia diagnoses, finding that biomarkers of hypo-
metabolism and structural atrophy showed 90.5% concordance with
clinical diagnoses, and further assisted with diagnostic subtyping.
Although offering limited benefit in two patients, the authors note
that PET/MRI reduced the need for sedation in distressed
cognitively‐impaired patients due to its relative simplicity and
reduced scanning time. Tahmasian et al.49 reported a similar benefit
of multimodal imaging for differentiating dementia subtypes. Using
18FDG‐PET/MRI, they found classification accuracies to be between
77.5% and 97.5% for subtypes including bvFTD, SD, and PNFA,
findings that were significantly superior to unimodal approaches.
Further support is provided by Schutz et al.48 who employed
both [11C]PIB and 18F‐florbetaben amyloid PET tracers, finding that
PET/MRI assisted diagnostic categorisation in 67% of patients inde-
pendent of MTL atrophy and amyloid load biomarkers. Furthermore,
82% of referrers noted the significant influence PET/MRI had on final
diagnoses. This positive reception was also reported by Kaltoft
et al.44 who found that radiologist confidence ratings for the diag-
nostic classification of memory clinic patients were significantly
greater for PET/MRI images compared to PET/CT. Additionally, PET/
MRI identified significantly more vascular pathologies, which altered
diagnoses in 17% of patients. Furthermore, reclassification of pa-
tients using PET/MRI had a major clinical impact on management in
22% of patients. This is the only study directly comparing the two
hybrid techniques within this review, a comparison that is desper-
ately needed to better assess the extent to which PET/MRI can aid
clinical practice.
5 | CONCLUSION
This review examined studies published in the last 5 years on the use
of PET/MRI in dementia in order to identify the advantages and
possible disadvantages of this hybrid method for clinical application.
Overall, new data studies investigating the role of the hippocampus
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and DMN in neurodegenerative disease demonstrate the added
insight provided by PET/MRI into underlying anatomical, metabolic,
and functional changes associated with disease progression, and
importantly, how such processes are interlinked. Further to this,
research accounting for the perceived diagnostic utility and overall
approachability of PET/MRI for radiologists demonstrates its capa-
bility of matching, and arguably surpassing current methods used in
dementia care, although further studies providing direct comparisons
with PET/CT are critical. In conclusion, whilst PET/MRI currently
exists as a predominantly research‐based tool in dementia, the cur-
rent review demonstrates that not only does PET/MRI offer
comparative feasibility to unimodal methods and PET/CT, it could
improve diagnostic classification of dementia patients, with impor-
tant implications for clinical management.
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